Latest Content

Review news from the last week in psychiatry.

Leading psychiatric organizations respond to federal push for deprescribing.

Renaming borderline personality disorder fails to address the condition's complexity; keeping the term preserves key clinical meaning, including structural traits and stress-related psychotic symptoms.

Psilocybin therapy shows fast, lasting relief for depression; clinicians discuss trial hurdles and emerging promise for PTSD and addiction in this podcast.

Get real-time psychiatry conference highlights with video interviews, session takeaways, and quick clips from APA and psychopharmacology meetings.

Online tool personalizes antidepressant choice in primary care, cutting dropouts and improving 24-week depression and anxiety scores.

New psychiatry drugs target dementia agitation, ADHD, depression, TRD, and schizophrenia—see which novel mechanisms may reach the FDA next.

FDA clears MIND1 trial testing NRX-101 plus robotic TMS to curb suicidality in treatment-resistant depression, with military-focused sites.

Explore how neuromelanin-sensitive MRI noninvasively tracks long-term dopamine and noradrenaline system changes.

Learn how dual antipsychotics can mask the true cause of high prolactin, and how stepwise switches to aripiprazole or clozapine restore cycles.

New cohort and global data link teen high-potency cannabis use to higher psychosis, bipolar, and suicide risks. Here's what psychiatrists and mental health clinicians should know in the era of legalization.

HHS rolls out a plan to curb psychiatric overprescribing, pushing deprescribing guidance as APA and AFSP urge caution and access to care.